Renier Davide, Bellato Pierangelo, Bellini Davide, Pavesio Alessandra, Pressato Daniele, Borrione Anna
Biosurgery Division, Fidia Advanced Biopolymers S.r.L., Abano Terme, Padova, Italy.
Biomaterials. 2005 Sep;26(26):5368-74. doi: 10.1016/j.biomaterials.2005.01.053.
Autocrosslinked polysaccharide (ACP) gel is a fully biocompatible cross-linked derivative of hyaluronic acid, which has prolonged in vivo residence time and improved mechanical properties with respect to native hyaluronan for use in various surgical applications. The objective of this study was to assess the pharmacokinetic behaviour of ACP gel in dogs after intraperitoneal administration. Seven beagle dogs received intraperitoneal injections of tritium-labelled ACP gel. Blood samples were taken, and urine and faeces were collected until sacrifice, scheduled at various time points from 3 to 192 h after administration. Organs were removed from the animals at autopsy. Bodily fluid and organ samples were analysed for total and non-volatile radioactivity. Non-volatile radioactivity slowly appeared in plasma, with a median T(max) of 12 h, and then declined with a mean half-life of 69 h. Total radioactivity in plasma peaked later and declined more slowly, consistent with the formation of tritiated water. Little non-volatile radioactivity was found in any organs except the liver, where about 16% of the dose was present 72 h after administration, and the intestines, where the presence of radioactivity was probably due to a retention effect. A minor amount of non-volatile radioactivity was also found in the bone marrow. In summary, ACP gel administered into the peritoneal cavity is removed slowly by active initial catabolism at the injection site, and is then catabolised by well described physiological pathway of hyaluronan degradation with final release of simple molecules such as CO(2) and H(2)O. Given its in vivo residence time, ACP gel may be considered an ideal implantable surgical device.
自交联多糖(ACP)凝胶是透明质酸的一种完全生物相容性交联衍生物,与天然透明质酸相比,它在体内的停留时间延长,机械性能得到改善,可用于各种外科手术。本研究的目的是评估腹腔注射后ACP凝胶在犬体内的药代动力学行为。七只比格犬接受了腹腔注射氚标记的ACP凝胶。采集血样,并收集尿液和粪便直至处死,处死时间安排在给药后3至192小时的不同时间点。尸检时从动物体内取出器官。对体液和器官样本进行总放射性和非挥发性放射性分析。非挥发性放射性在血浆中缓慢出现,中位T(max)为12小时,然后以平均半衰期69小时下降。血浆中的总放射性峰值出现较晚且下降较慢,这与氚化水的形成一致。除肝脏外,在任何器官中均未发现少量非挥发性放射性,给药72小时后肝脏中约有16%的剂量,而在肠道中放射性的存在可能是由于滞留效应。在骨髓中也发现了少量非挥发性放射性。总之,腹腔内注射的ACP凝胶首先在注射部位通过活跃的初始分解代谢缓慢清除,然后通过透明质酸降解的既定生理途径进行分解代谢,最终释放出CO(2)和H(2)O等简单分子。鉴于其在体内的停留时间,ACP凝胶可被认为是一种理想的可植入手术装置。